Snapshot

The Abbreviated Pathway pathway has been developed by the Ministry of Health of Panama.

This pathway can be used where all therapeutic products.

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

When relevant, the agency relies on prior decisions from Australia Austria Belgium Canada Denmark EU-EMA Europe Finland France Germany Holland Iceland Ireland Italy Japan New Zealand Norway Spain Sweden Switzerland United Kingdom United States

60 days for the initial review. Questions are batched and the sponsor has 2 months to respond. Upon receipt of the responses, the agency has 30 days in which to render a decision.